Home Cart Sign in  
Chemical Structure| 153436-54-5 Chemical Structure| 153436-54-5

Structure of PD153035
CAS No.: 153436-54-5

Chemical Structure| 153436-54-5

PD153035

CAS No.: 153436-54-5

PD153035 is an EGFR tyrosine kinase inhibitor with an IC50 of 25 nM. PD153035 has anti-tumor effects and is used to study EGFR-related signaling pathways and cancer therapy.

Synonyms: AG1517; ZM 252868; NSC 669364

4.5 *For Research Use Only !

Cat. No.: A100205 Purity: 99+%

Change View

Size Price

US Stock

Global Stock

In Stock
50mg ł§ÿ¶ÊÊ Inquiry Inquiry
100mg łÍî¶ÊÊ Inquiry Inquiry
250mg łÿî¶ÊÊ Inquiry Inquiry
1g łÇÿ˶ÊÊ Inquiry Inquiry
5g łÍóʶÊÊ Inquiry Inquiry
10g łó§î¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 50mg

    ł§ÿ¶ÊÊ

  • 100mg

    łÍî¶ÊÊ

  • 250mg

    łÿî¶ÊÊ

  • 1g

    łÇÿ˶ÊÊ

  • 5g

    łÍóʶÊÊ

  • 10g

    łó§î¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PD153035

CAS No. :153436-54-5
Formula : C16H14BrN3O2
M.W : 360.21
SMILES Code : COC1=CC2=NC=NC(NC3=CC=CC(Br)=C3)=C2C=C1OC
Synonyms :
AG1517; ZM 252868; NSC 669364
MDL No. :MFCD00934896
InChI Key :LSPANGZZENHZNJ-UHFFFAOYSA-N
Pubchem ID :4705

Safety of PD153035

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Related Pathways of PD153035

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR, Ki:5.2 pM

In Vitro:

Cell Line
Concentration Treated Time Description References
SKOV3 cells 1 µM 1 hour PD153035 and AG1478 blocked EGF-induced EGFR activation (phosphorylation at Tyr 1068), but had no effect on EGF-induced EGFR down-regulation. PMC2519958
CaOV3 cells 1 µM 1 hour PD153035 inhibits EGF-induced EGFR, and downstream AKT/ERK activation, but cannot reverse EGF-induced EGFR down-regulation. PMC2519958
A549 cells 1 μM 1 hour To investigate the inhibitory effect of PD153035 on the EGF signaling pathway and its impact on mitochondrial dynamics. Results showed that PD153035 inhibits the EGF signaling pathway and promotes mitochondrial fusion. PMC8870661
BeWo cells 0-1 μM 24 hours PD153035 inhibited EGFR phosphorylation and reduced Ki67 expression, indicating that EGFR is activated without exogenous stimulation. PMC11115170
BeWo cells 0-1 μM 24 hours PD153035 inhibited EGFR phosphorylation and partially reversed the enhanced proliferation observed following SHP-1 knockdown PMC11115170
Normal human epidermal keratinocytes (NHEKs) 300 or 600 nM 24 hours PD153035 significantly inhibited scratch-induced CCL20 upregulation and decreased baseline CCL20 production in non-scratched controls PMC7013594
AGS gastric epithelial cells 5 µM 30 min pretreatment followed by H. pylori infection for 4 hours Inhibited H. pylori-mediated Egr-1 upregulation, demonstrating EGFR transactivation plays a role in this process PMC1774684
PC-3 cells 500 nM 72 hours Reversed EGF-induced decrease in miR-200c expression PMC6158022
DU-145 cells 500 nM 72 hours Reversed EGF-induced decrease in miR-200c expression PMC6158022
HCT116 colon cancer cells 0-20 μM 72 hours To evaluate the effect of PD153035 on proliferation and apoptosis of colon cancer stem cells. Results showed that PD153035 inhibited tumorosphere formation in a dose-dependent manner. PMC6495284

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Schizophrenia animal model Intraventricular infusion 1.0, 0.1 or 0.01 mg/ml 14 days PD153035 ameliorated the deficits in startle response and prepulse inhibition in a dose-dependent manner and reduced the bursting activity of nigral dopamine neurons. PMC3641415
Mice Partial liver transplantation model Intraperitoneal injection 30 mg/kg Injected immediately after transplantation PD153035 inhibited EGFR activity, significantly reducing BrdU labeling and mitotic index in 50%-size liver grafts and largely abrogated the stimulation of regeneration by AR in 30%-size liver grafts. PMC3409348

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.78mL

0.56mL

0.28mL

13.88mL

2.78mL

1.39mL

27.76mL

5.55mL

2.78mL

References

 

Historical Records

Categories